FundingPublic signal4 days ago
What changed
Raised $133M in Series B funding, led by Advent Life Sciences and British Business Bank.
The company said the funding supports support entry into the clinic and the generation of clinical data for its two lead TCR-CD3 bispecific programmes in oncology and autoimmune diseases.
What nextsupport entry into the clinic and the generation of clinical data for its two lead TCR-CD3 bispecific programmes in oncology and autoimmune diseases.
Where help may be relevant AfterRaise intelligenceScientific advisersTrial operationsSpecialist suppliers
Approach preferences not yet specified